A Randomized, Double-Blind, Placebo-Controlled Study To Evaluate the Safety and Efficacy of Daclizumab HYP Monotherapy in Relapsing-Remitting Multiple Sclerosis: Primary Results of the SELECT Trial (S01.005)

Authors :: Randy Robinson
Eva Havrdova
Ernst-Wilhelm Radue
Jacob Elkins
Xavier Montalban
Krzysztof Selmaj
Ralf Gold
Katherine Riester
Dusan Stefoski
Gilmore O'neill
Gavin Giovannoni
Source :: Neurology. 78:S01.005-S01.005
Publication Year :: 2012
Publisher :: Ovid Technologies (Wolters Kluwer Health), 2012.

Subjects :: Double blind
medicine.medical_specialty
Daclizumab HYP
Relapsing remitting
business.industry
Multiple sclerosis
Internal medicine
Physical therapy
Placebo-controlled study
Medicine
Neurology (clinical)
business
medicine.disease

Tools